1
|
Zhu Y, Sun L, Wang Y, Wang J, Wang Y, Li J, Wang L, Guo Y. Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study. Hum Vaccin Immunother 2024; 20:2372884. [PMID: 38957938 PMCID: PMC11225913 DOI: 10.1080/21645515.2024.2372884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Accepted: 06/22/2024] [Indexed: 07/04/2024] Open
Abstract
To fully understand the safety of DTaP-IPV/Hib vaccination, we evaluated the differences between DTaP-IPV/Hib co-administration and separate administration of the DTaP, IPV and Hib vaccines (DTaP+IPV+Hib) based on adverse events following immunization (AEFI). All AEFI reported in Hebei Province, China, between 2020 and 2022 were included in this study. The risk difference (RD%), relative risk (RR), and Chi-square value were used to compare the differences in reported rates of AEFI between the DTaP-IPV/Hib and DTaP+IPV+Hib groups. From 2020 to 2022, 130 AEFI cases were reported in Hebei Province after DTaP-IPV/Hib vaccination, corresponding to an AEFI reported rate of 66.9/million doses, which was significantly lower than that for DTaP+IPV+Hib (9836 AEFI with a reported rate of 637.8/million doses). The overall reported rate of non-severe AEFI for DTaP+IPV+Hib vaccines was 9.5 times that of DTaP-IPV/Hib vaccination [95% confidence interval (CI): 8.0, 11.3]. Meanwhile, the reported rate of AEFI among infants aged 0-1 y was 9.8 times higher for DTaP+IPV+Hib than for DTaP-IPV/Hib (95% CI: 8.2, 11.7). DTaP+IPV+Hib vaccination also resulted in higher risks of high fever, localized redness and swelling, localized induration, and allergic rash compared with DTaP-IPV/Hib vaccination. The risk of AEFI, which were mostly mild reaction, was higher after vaccination with DTaP+IPV+Hib than after DTaP-IPV/Hib vaccination.
Collapse
Affiliation(s)
- Yiqing Zhu
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| | - Li Sun
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| | - Yihan Wang
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| | - Jinghui Wang
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| | - Yafei Wang
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| | - Jing Li
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| | - Lina Wang
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| | - Yu Guo
- Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China
| |
Collapse
|
2
|
Feng G, Shao M, Wang J, Huang L, Tan J, Jiang Z, You W, Li Y, Yang Y, Li J, Wang Y. Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months. Vaccines (Basel) 2024; 12:123. [PMID: 38400106 PMCID: PMC10892248 DOI: 10.3390/vaccines12020123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 12/24/2023] [Accepted: 01/09/2024] [Indexed: 02/25/2024] Open
Abstract
BACKGROUND The multidose Sabin-strain inactivated poliovirus vaccine (sIPV) has the potential to significantly aid in the eradication of poliomyelitis, particularly in low- and middle-income countries. As part of a phase III clinical trial in which infants were given three doses of primary immunization at 2, 3, and 4 months of age, this study aimed to evaluate immune persistence following primary immunization, as well as the safety and immunogenicity of a booster of the 5-dose sIPV in infants aged 18 months. METHODS Infants aged 18 months were given one booster dose of 5-dose sIPV in stage one, which was open-label. Unblinding was performed for stage two after completing primary immunization, which was randomized, blinded, and controlled; infants aged 18 months in the test group I-III, IPV group, and single-dose sIPV group were given one booster dose of 5-dose sIPV, conventional IPV, and single-dose sIPV, respectively, in stage two. RESULTS This study included 1438 infants in the immune persistence and safety set and 1387 infants in the booster per-protocol set. Fourteen months after primary immunization, the seropositivity rates (≥1:8) for types 1-3 were 100%, 99.88%, and 99.53% in the 5-dose sIPV groups; 100%, 98.97%, and 97.23% in the IPV group; and 99.66%, 100%, and 99.66% in the single-dose sIPV group. A total of 30 days after booster immunization, the seropositivity rates (≥1:8) of 3 serotypes in all the groups reached 100%. The geometric mean titers of neutralizing antibodies for types 1-3 in the 5-dose sIPV group were 9962.89, 10273, and 7870.21, with geometric mean increases of 15.76, 33.15, and 24.5, compared to the pre-booster level. The overall incidence of adverse reactions was 8.97%, with fever being the most common, observed at rates of 7.1%, 5.52%, and 7.96% in the 5-dose sIPV, IPV, and single-dose groups, respectively (p = 0.4845). CONCLUSIONS The 5-dose sIPV has shown promising immune persistence and robust immune response following a booster immunization, coupled with an acceptable safety profile.
Collapse
Affiliation(s)
- Guangwei Feng
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Ming Shao
- National Institute for Food and Drug Control, Beijing 100050, China;
| | - Jianfeng Wang
- Sinovac Biotech Co., Ltd., Beijing 100085, China; (J.W.); (J.T.)
| | - Lili Huang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Jian Tan
- Sinovac Biotech Co., Ltd., Beijing 100085, China; (J.W.); (J.T.)
| | - Zhiwei Jiang
- Beijing Key Tech Statistics Technology, Beijing 100025, China;
| | - Wangyang You
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Yurong Li
- Sinovac Life Sciences Co., Ltd., Beijing 102629, China;
| | - Yonghui Yang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Jing Li
- Sinovac Biotech Co., Ltd., Beijing 100085, China; (J.W.); (J.T.)
| | - Yanxia Wang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| |
Collapse
|
3
|
Yang K, Kim H, Ortiz E, Huoi C, Kang J. Post-Marketing Safety Surveillance of a Childhood Pentavalent Diphtheria-Tetanus-Acellular Pertussis-Polio and Haemophilus influenzae Type B (DTaP-IPV//Hib) Vaccine in South Korea. Infect Dis Ther 2023; 12:499-511. [PMID: 36520326 PMCID: PMC9925623 DOI: 10.1007/s40121-022-00724-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 11/03/2022] [Indexed: 12/23/2022] Open
Abstract
INTRODUCTION PENTAXIM™ (Sanofi), DTaP-IPV//Hib, a pentavalent combination vaccine for protection against diphtheria, tetanus, pertussis, poliomyelitis, and invasive infections caused by Haemophilus influenzae type b, has been licensed in South Korea by the Ministry of Food and Drug Safety (MFDS) on May 9, 2016, and is currently used in routine vaccination. The aim of this phase IV study, conducted as a post-licensure commitment in South Korea, was to evaluate the safety of the DTaP-IPV//Hib vaccine when administered in infants at 2, 4, and 6 months of age in the real-world clinical practice. METHODS This multicenter, observational, post-marketing surveillance (PMS) study was conducted in real-world practice in South Korea. Infants aged 2 months or older were enrolled across seven centers from July 31, 2018 to February 11, 2020. The study outcomes included occurrence, time to onset, duration, intensity, and causality assessment (for unsolicited adverse events [AEs] only) for several pre-listed solicited injection-site and systemic reactions, unsolicited AEs, and serious adverse events (SAEs). RESULTS Data from 619 participants were included in the safety analysis. Overall, 618 AEs were reported by 273 (44.1%) participants consisting of 121 solicited injection-site reactions (15.4%), 344 solicited systemic reactions (24.6%), and 153 unsolicited AEs (15.7%) of which, 124 were unexpected AEs (12.9%) (regardless of intensity). None of the unsolicited AEs were reported to have a causal relationship with the study vaccine. One SAE of pyrexia (solicited reaction) was reported. Most AEs were of mild intensity, and all participants recovered. CONCLUSION This PMS study of the DTaP-IPV//Hib vaccine confirmed its safety profile in a real-life setting in South Korea and justified that the vaccine is well tolerated when used in infants aged 2 months or older for the primary series.
Collapse
Affiliation(s)
- Kuhyun Yang
- Medical Affairs, Sanofi, Seoul, Republic of Korea
| | - Hyunjung Kim
- Medical Department, Sanofi, Seoul, Republic of Korea
| | | | | | - Jinhan Kang
- The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
| |
Collapse
|
4
|
Yu J, He H, Zhang Y, Gao Y, Chen C, Xu J, Xu L, Zhang X, Zhou Q, Zhu Y, Tang X, Guo Y, Chen Z, Shao Z. Burden of whooping cough in China (PertussisChina): study protocol of a prospective, population-based case-control study. BMJ Open 2022; 12:e053316. [PMID: 35273046 PMCID: PMC8915282 DOI: 10.1136/bmjopen-2021-053316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
INTRODUCTION Pertussis is one of the top 10 diseases of children under 10 years of age, and the few vaccine-preventable diseases who is on a rise in China in recent years; however, the true burden of pertussis, including age-stratified incidence and risk factors of severe sequelae, are under-recognised. We aim to estimate the health burden of laboratory-confirmed pertussis by age groups, considering the setting of illness onset (ie, in community, outpatient and inpatient), in a Chinese population (~2.23 million in total) at two sites. METHODS AND ANALYSIS This paper describes the study design of a 1-year, prospective, age-stratified and population-based case-control study, including site selection, study population, case registry, ascertainment and enrolment, control recruitment, follow-up of case, microbiological methods, data collection, quality control activities and statistical methods used to generate incidence estimates. During June 2021 through May 2022, registry of suspected pertussis cases (namely chronic/persistent cough) will be conducted in several participating hospitals (SHs) at the two sites, which are selected based on Healthcare Utilisation and Attitudes Surveys (HUAS) carried out before study initiation. A case-control study will be conducted in the SHs and we aim to enrol a total of 1000 suspected pertussis cases (ie, all hospital admissions and the first 1-3 outpatient visits each week each hospital) and 2000 frequency matched healthy controls in community. Our primary study outcome, the laboratory-confirmed Bordetella pertussis infection, will be determined by a comprehensive laboratory methods and procedures (ie, culture, PCR and serological tests) in both cases and controls at enrolment and during 60-day's follow-up visits. Finally, data from HUAS (ie, population size), case registry (ie, the total number of suspected pertussis cases) and case-control study (ie, the prevalence or population attributable fraction of Bordetella pertussis) will be combined to calculate incidence and its 95% CI through bootstrap method. Epidemiological analyses will be conducted to determine the risk factors associated with severe sequelae of pertussis. ETHICS AND DISSEMINATION This study has been approved by Chinese Centre for Disease Control and Prevention's Institutional Review Board (no. ICDC-202110). Results will be disseminated via academic presentations and publication in peer-reviewed journals, and will provide valuable scientific data and some new insights into the incidence, aetiology and risk factors for severe sequelae of pertussis to academic societies and the public health authorities who is currently struggling and fighting against this burdensome disease worldwide.
Collapse
Affiliation(s)
- Jianxing Yu
- National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P.R.China
| | - Hanqing He
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Binjiang District, China
| | - Yanyang Zhang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan Province, China
| | - Yuan Gao
- National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P.R.China
| | - Chuanwei Chen
- Yongcheng Center for Disease Control and Prevention, Yongcheng, Dongcheng District, China
| | - Juan Xu
- National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P.R.China
| | - Li Xu
- National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P.R.China
| | - Xiaoxiao Zhang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan Province, China
| | - Qianqian Zhou
- Yongcheng Center for Disease Control and Prevention, Yongcheng, Dongcheng District, China
| | - Yao Zhu
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Binjiang District, China
| | - Xuewen Tang
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Binjiang District, China
| | - Yonghao Guo
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan Province, China
| | - Zhiping Chen
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Binjiang District, China
| | - Zhujun Shao
- National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P.R.China
- State Key Laboratory for Infectious Disease Prevention and Control, Beijing, P.R.China
| |
Collapse
|
5
|
Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. J Infect Chemother 2020; 26:651-659. [DOI: 10.1016/j.jiac.2019.11.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Revised: 11/13/2019] [Accepted: 11/29/2019] [Indexed: 11/19/2022]
|
6
|
Comparing Haemophilus influenzae type b conjugate vaccine schedules: a systematic review and meta-analysis of vaccine trials. Pediatr Infect Dis J 2013; 32:1245-56. [PMID: 24145955 DOI: 10.1097/inf.0b013e31829f0a7e] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND The optimal schedule and the need for a booster dose are unclear for Haemophilus influenzae type b (Hib) conjugate vaccines. We systematically reviewed relative effects of Hib vaccine schedules. METHODS We searched 21 databases to May 2010 or June 2012 and selected randomized controlled trials or quasi-randomized controlled trials that compared different Hib schedules (3 primary doses with no booster dose [3p+0], 3p+1 and 2p+1) or different intervals in primary schedules and between primary and booster schedules. Outcomes were clinical efficacy, nasopharyngeal carriage and immunological response. Results were combined in random-effects meta-analysis. RESULTS Twenty trials from 15 countries were included; 16 used vaccines conjugated to tetanus toxoid (polyribosylribitol phosphate conjugated to tetanus toxoid). No trials assessed clinical or carriage outcomes. Twenty trials examined immunological outcomes and found few relevant differences. Comparing polyribosylribitol phosphate conjugated to tetanus toxoid 3p+0 with 2p+0, there was no difference in seropositivity at the 1.0 μg/mL threshold by 6 months after the last primary dose (combined risk difference -0.02; 95% confidence interval: -0.10, 0.06). Only small differences were seen between schedules starting at different ages, with different intervals between primary doses, or with different intervals between primary and booster doses. Individuals receiving a booster were more likely to be seropositive than those at the same age who did not. CONCLUSIONS There is no clear evidence from trials that any 2p+1, 3p+0 or 3p+1 schedule of Hib conjugate vaccine is likely to provide better protection against Hib disease than other schedules. Until more data become available, scheduling is likely to be determined by epidemiological and programmatic considerations in individual settings.
Collapse
|
7
|
Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J 2012; 31:e24-30. [PMID: 22157567 DOI: 10.1097/inf.0b013e318242460a] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
OBJECTIVE To assess antibody persistence after vaccination with a new, fully liquid, hexavalent DTaP-IPV-Hep B-PRP-T vaccine at 18 months of age versus licensed DTaP-IPV//PRP-T and hepatitis B (Hep B) vaccines, and to assess the immunogenicity and safety of a subsequent DTaP-IPV//PRP-T booster. METHODS A phase III, open-label, single-center study was conducted. Infants previously primed with 3 doses of DTaP-IPV-Hep B-PRP-T (Hexaxim: N = 232 [group 1]) or DTaP-IPV//PRP-T and hepatitis B vaccine (Pentaxim + Engerix B Pediatrico: N = 226 [group 2]) at 2, 4, and 6 months of age received a DTaP-IPV//PRP-T booster at 18 months of age. Antibodies were measured before and 1 month after booster vaccination. Safety was evaluated from parental reports. Analyses were descriptive. RESULTS Antibody persistence was high and similar in each group for each antigen except for Hep B, for which the percentage (95% confidence interval) of participants with a titer of ≥ 10 mIU/mL was higher in group 2 (99.5% [97.5%, 100.0%]) than in group 1 (85.5% [80.3%, 89.8%]). Postbooster seroprotection (diphtheria, tetanus, inactivated poliovirus, polyribosyl-ribitol phosphate) and serconversion (pertussis toxoid, filamentous hemagglutinin) rates were high and similar in each group, and geometric mean antibody concentrations increased markedly in both groups. Safety after the booster vaccination was good and independent of the primary-series vaccine, although one serious adverse event of convulsions was considered to be vaccine related. CONCLUSIONS The DTaP-IPV/PRP-T booster vaccination at 18 months of age was similarly immunogenic and well tolerated after primary-series vaccination with either the investigational hexavalent vaccine or the reference pentavalent vaccine. This confirms the suitability of a booster vaccination of DTaP-IPV//PRP-T after a primary series of the new DTaP-IPV-Hep B-PRP-T vaccine.
Collapse
|